| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to pharmaceutical composition, containing compound of formulaorfor prevention or treatment of diseases, associated with oxidative stress, selected from group, consisting of MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke episodes), MERRF syndrome (myoclonic epilepsy with ragged red fibres) or Kearns-Sayre syndrome, arrhythmia, cardioplegia or myocardium infarction. in formula (1) na stands for 1 or 2, Arepresents 5-membered heteroaryl or heterocycle, each of which has 2 heteroatoms, selected from N, O and S, Rrepresents R-X-B-X?-, Brepresents direct bond, Xand X?independently on each other represent direct bond or -OC(O)-, Rrepresents hydrogen or 6-9-membered monocyclic or condensed cyclic heterocycle or heteroaryl, each of which has from 1 to 3 heteroatoms, selected from N, O and S, and is optionally substituted with oxo or C-C-alkyl, Rrepresents -(CRR)-Y-R?pa stands for number from 0 or 1, Yrepresents direct bond or -O-, Rrepresents hydrogen or phenyl, R, R, R, Rrepresent hydrogen, Rrepresents -(CH)-D-R-, Drepresents C-cycloalkyl or 6-membered heterocycle, which has 1 heteroatom, selected from N, S and O. Radical values for formula (2) are give in invention formula.EFFECT: obtaining compositions for prevention or treatment of diseases, associated with oxidative stress.19 dwg, 5 tbl, 3 ex |
